Cytodyn Inc (CYDY)

[Apollo_]

CytoDyn Makes Headway for HIV Treatment Substitution

.... If CytoDyn’s Phase 2b Treatment Substitution study is successful it could see tremendous commercial opportunity as treatment substitution in HIV therapies. In a country where treated cases of HIV cases are estimated at over 604,000, the possibility that missed opportunities exist is certain. For example, patients who tested positive for HIV tropism for CCR5 account for 65% (390,400 patients). The cost of HAART for this many patients is about $7 billion.

CytoDyn has submitted the clinical trial protocol for Phase 2b in February and expects to conduct patient screenings very soon. It could start rolling out trials by May and evaluate results from June to September 2014.


http://ireport.cnn.com/docs/DOC-1108726